Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MultiStem in ARDS (MUST-ARDS)
NCT02611609Phase 2Completed
- Sponsor
- Healios
- Start
- Jan 2016
- Primary completion
- Sep 2018
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of invimestrocel in acute respiratory distress syndrome (ARDS) (4 cohorts), sponsored by Healios. Primary endpoints: Frequency of sustained hypoxemia or hypotension at 4 hours and Suspected Unexpected Serious Adverse Reactions at 24 hours. Started Jan 2016; status: completed.
02
Drugs
invimestrocel
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT02611609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611609.